Presenting at AHS 2022, researchers determined the effect of generalized anxiety disorder on the responsiveness of BoNT-A treatment from pediatric patients with chronic migraine.
In a global, phase 3 trial, researchers evaluated the efficacy of ganaxolone as an adjunctive treatment compared to placebo for major motor seizures in patients with CDKL5 deficiency disorder.
Researchers sought to establish whether frequent use of a combined biofeedback-virtual reality device is associated with improvements in chronic migraine, especially in patients refractory to pharmacotherapy.
In a study presented at MDS 2021, researchers assessed whether patients with tic disorders with or without major psychoses were at risk of developing tardive dyskinesia.
CMSC 2019 Coverage
Age- and sex-stratified comorbidity and concomitant medication use has been found among individuals with MS who have newly initiated disease-modifying drugs.
Currently, there are no US consensus on best clinical practice guidelines that incorporate multispecialty recommendations for evaluating cognitive impairment that are thought to be due to Alzheimer's disease and Related Dementias (ADRD) for use by physicians and nurse practitioners.
AAN 2018 Coverage
Researchers sought to assess outcomes in hospitalized patients with comorbid Parkinson disease and major depressive disorder following administration of deep brain stimulation.
Researchers examined whether there are clinical features or treatments associated with neuropsychiatric outcomes in BECTS.
AAN 2015 Coverage
The system is currently being assessed for its use in stroke rehabilition in the Phase 3 supplemental study 'E-FIT', involving 60 patients.
In-Depth Focus From AAN: Movement Disorders
Jessica Karl, PA-C, of Rush University Medical Center in Chicago, discusses her research on the utility and feasibility of deep brain stimulation in patients with Huntington's disease. Scroll below the video for the full transcript.